Item 2.02 Results of Operations and Financial Condition.
On
Although it has not finalized its full financial results for the fourth quarter
and fiscal year ended
The information contained in Item 2.02 of this Current Report on Form 8-K and
Exhibit 99.1 attached hereto is unaudited and preliminary and does not present
all information necessary for an understanding of the Company's financial
condition as of
The information contained in Item 2.02 of this Current Report on Form 8-K and Exhibit 99.1 attached hereto is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act") or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.
Item 9.01. Exhibits (d) Exhibits Exhibit No. Description 99.1 Press Release issued byKymera Therapeutics, Inc. datedJanuary 10, 2023 , furnished herewith. 104 Cover Page Interactive Data (embedded within the Inline XBRL document).
--------------------------------------------------------------------------------
© Edgar Online, source